Actively Recruiting
Network Neurofeedback Using 7-Tesla MRI to Reduce Rumination Levels in Depression
Led by Icahn School of Medicine at Mount Sinai · Updated on 2025-08-17
80
Participants Needed
1
Research Sites
194 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with major depressive disorder (MDD) exhibit increased levels of rumination (i.e. repetitive thinking and focus on negative mood states) which have been found to increase the risk of depressive relapse. The ability to reduce rumination levels among these patients is greatly needed. Rumination is known to be associated with the default mode network (DMN) region activity. Implementing the Dependency Network Analysis (DEPNA), a recently developed method by the research team to quantify the connectivity influence of network nodes, found that rumination was significantly associated with lower connectivity influence of the left medial orbitofrontal cortex (MOFC) on the right precuneus, both key regions within the DMN. This study implements the first real-time fMRI neurofeedback (Rt-fMRI-NF) network-based protocol for up-regulation of the MOFC influence on the precuneus in patients with MDD to reduce rumination levels. This will allow for more accurate explicit brain connections modulation than the standard single brain region activity; creating a larger opportunity for target clinical neuromodulation treatment in individuals with MDD.
CONDITIONS
Official Title
Network Neurofeedback Using 7-Tesla MRI to Reduce Rumination Levels in Depression
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18-65 years who either meet DSM-5 Axis Disorders (SCID) or the Mini International Neuropsychiatric Interview (MINI) for major depressive disorder (MDD) with a current major depressive episode OR do not meet criteria for any current or past psychiatric diagnoses
- Participants must understand English well enough to consent and participate fully in all study tests and examinations
You will not qualify if you...
- Any current or history of schizophrenia, other psychotic disorders, neurodevelopmental disorders, neurocognitive disorders, or active substance use disorder within the past 6 months
- Unstable medical illness or use of any medication affecting the central nervous system within 1 week of the MRI scan
- Pregnancy
- Currently hospitalized in inpatient psychiatric units at Mount Sinai Hospital or involuntarily admitted/court-ordered
- Judged to be at serious and imminent suicidal or homicidal risk by a study-affiliated psychiatrist or MD
- Contraindications to MRI
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Icahn School Of Medicine at Mount Sinai
New York, New York, United States, 10029
Actively Recruiting
Research Team
G
Grace S. Butler, BA
CONTACT
R
Rachel Krasner, BA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here